Loading paragraph...
Today's Biggest Stock Gainers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| CYCN | Cyclerion Therapeutics | $6.31 | $4.76 | 307.10% | 248.2M | $6.1M | $1.03$8.48 |
| AGPU | Axe Compute | $3.37 | $1.75 | 108.03% | 77.4M | $5.5M | $1.03$32.10 |
| ELAB | Pmgc | $11.05 | $5.06 | 84.47% | 32.6M | $3.2M | $1.62$466.20 |
| SST | System1 | $5.34 | $2.32 | 76.82% | 15.4M | $24M | $1.35$15.00 |
| MGRT | Mega Fortune | $11.41 | $4.95 | 76.63% | 94.8K | $89M | $1.50$17.51 |
| RYM | Rythm | $30.10 | $11.80 | 64.48% | 5.2K | $39M | $13.22$53.65 |
| RENX | RenX Enterprises | $2.63 | $0.85 | 47.75% | 84.5M | $4.1M | $1.42$47.20 |
| NPT | Texxon | $10.92 | $3.44 | 45.92% | 379.7K | $166M | $3.14$22.38 |
| FGI | Fgi Industries | $5.15 | $1.42 | 38.07% | 446.2K | $7.2M | $2.28$12.62 |
| RGC | Regencell Bioscience | $35.10 | $9.67 | 38.03% | 22.9K | $13B | $0.58$83.60 |
| TH | Target Hospitality | $12.50 | $3.22 | 34.70% | 218.6K | $929M | $5.97$13.24 |
| GURE | Gulf Resources | $7.88 | $1.63 | 26.00% | 88.6K | $8.6M | $3.47$11.83 |
| GRDX | GridAI Technologies | $2.53 | $0.51 | 25.29% | 217.4K | $6.8M | $0.97$5.84 |
| BCG | Binah Capital Group | $2.49 | $0.48 | 23.88% | 30.4M | $33M | $1.36$3.44 |
| QVCGP | Qvc Group | $3.11 | $0.58 | 22.92% | 42.3K | - | $1.28$28.39 |
| AGL | Agilon Health, Inc. | $9.70 | $1.79 | 22.63% | 23.2K | $3.3B | $7.48$152.00 |
| RZLV | Rezolve Ai Plc | $3.14 | $0.58 | 22.46% | 2.3M | $1.0B | $1.07$8.45 |
| SHAZ | SharonAI | $27.84 | $5.11 | 22.46% | 681.2K | $364M | $1.85$178.00 |
| HTT | High Templar Tech | $2.37 | $0.43 | 22.16% | 23.9K | $197M | $1.88$5.08 |
| WBX | Wallbox | $3.01 | $0.53 | 21.37% | 378 | $44M | $2.30$8.00 |
| TPTA | Terra Property Trust | $21.00 | $3.53 | 20.17% | 11.9K | - | $8.75$24.12 |
| VWAV | VisionWave | $5.68 | $0.94 | 19.83% | 4.1K | $93M | $2.06$18.41 |
| ADAG | Adagene | $4.69 | $0.77 | 19.64% | 3.4K | $185M | $1.30$4.70 |
| ALEC | Alector | $2.55 | $0.40 | 18.61% | 82.3K | $237M | $0.87$3.40 |
| EEIQ | EpicQuest Education Group International | $10.49 | $1.59 | 17.86% | 1M | $13M | $1.90$27.84 |
| VATE | Innovate | $6.68 | $1.00 | 17.61% | 1K | $78M | $3.75$8.28 |
| LINT | Direxion Shares ETF Trust - Direxion Daily Intc Bull 2x ETF | $37.98 | $5.45 | 16.75% | 166.6K | - | $23.87$57.26 |
| FOXX | Foxx Development | $5.28 | $0.52 | 10.92% | 11.4K | $33M | $1.71$8.88 |
Related Articles
Featured Article
The Best Stocks to Invest $1,000 in Right Now
Marc Guberti|Mar 14, 2026
Investing $1,000 in the right stocks can result in market-beating returns.
This Under-the-Radar Stock Could Be the Simplest Way to Build Long-Term Wealth
Marc Guberti|Jan 22, 2026
Rezolve AI looks like a hot pick as annual recurring revenue projections indicate big growth is on the way.
This Stock Soared 9,800% in 2025. Here's 1 Key Reason Why Investors Are Piling In (Spoiler: It's Regencell Bioscience Holdings (RGC) Stock)
Selena Maranjian|Nov 24, 2025
Is the stock likely to keep surging? The answer seems pretty clear.
Why Rezolve AI Stock Was a Scorcher in September
Eric Volkman|Oct 7, 2025
Investors tended to focus on the positive during the month.
3 Pot Stocks to Watch in May
James Halley|May 7, 2022
The three are due to report first-quarter earnings this month.
2 Underrated Growth Stocks That Could Be Better Buys Than Tesla
David Jagielski, CPA|Nov 22, 2021
They are much smaller companies that possess significant long-term growth potential.
Don't Miss What Sent These 2 Little-Known Nasdaq Newsmakers Soaring
Dan Caplinger|Jul 2, 2021
One of these companies is making big waves.
What Company Will Eli Lilly Buy Next?
David Haen|Jan 23, 2020
Following the announced buyout of Dermira, Eli Lilly’s management said more acquisitions are in store for 2020.
Biotech’s Year-End To-Do List
David Haen|Dec 7, 2019
The remaining weeks of December are chock-full of clinical trial results and FDA approval decisions that savvy investors can take advantage of.
2 Biotech Stocks Fighting Alzheimer’s Disease to Own Now
David Haen|Nov 9, 2019
No new drugs have been approved for Alzheimer’s disease since 2003. However, new approaches may soon bring options for the 5.7 million Americans suffering from the disease.
